Hims & Hers to Acquire Eucalyptus in Deal Valued Up to $1.15 Billion
Hims & Hers Health, Inc. has entered into an agreement to acquire Eucalyptus for up to $1.15 billion, consisting of $240 million upfront, $710 million in deferred payments, and up to $200 million in earnouts. The acquisition aims to expand Hims & Hers' global digital health footprint and product reach, with closing expected mid-fiscal 2026 pending regulatory approvals. Up to 60% of certain deferred and earnout amounts may be settled in Hims & Hers Class A shares.
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has initiated an investigation into Hims & Hers Health, Inc. (NYSE: HIMS) for potential securities law violations. This follows an FDA statement regarding GLP-1 active pharmaceutical ingredients in non-FDA-approved compounded drugs marketed by companies like Hims & Hers, and a lawsuit by Novo Nordisk to prevent the company from selling compounded weight-loss drugs. Shares of Hims & Hers fell by over 17.8% on February 9, 2026, due to this news.
Behavioral Patterns of HIMS and Institutional Flows
This article analyzes Hims & Hers Health Inc. (NASDAQ: HIMS) using AI models, identifying weak sentiment across all time horizons and supporting a short bias. It provides three distinct institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss levels. The analysis also highlights elevated downside risk due to the lack of long-term support signals.
Hedge funds bet big against Hims & Hers Health before Wegovy showdown, Hazeltree data shows
Hedge funds significantly increased their short positions against Hims & Hers Health in January, just prior to the online telehealth firm's dispute with Novo Nordisk over Hims' cut-price weight-loss pill. Hims withdrew its compounded Wegovy version after FDA scrutiny and faced lawsuits from Novo Nordisk, causing its share price to drop sharply. This increased short interest highlights investor concerns about Hims' access to the weight-loss market.
Assessing Hims & Hers Health (HIMS) Valuation After Regulatory And Legal Pressure On GLP 1 Offerings
Hims & Hers Health (HIMS) has faced significant legal and regulatory pressure, including a patent lawsuit from Novo Nordisk and FDA scrutiny over its GLP-1 offerings, leading to a sharp share price reset. Despite widespread undervaluation narratives from analysts, the company's valuation against industry P/E ratios suggests a premium that leaves little room for error. Investors are encouraged to consider these risks and potential growth trajectories when evaluating HIMS.
The Price Is Right For Hims & Hers Health, Inc. (NYSE:HIMS) Even After Diving 46%
Hims & Hers Health, Inc. (NYSE:HIMS) has seen its share price drop by 46% in the last month and 60% over the past year. Despite this significant decline, its price-to-earnings (P/E) ratio of 29.3x remains higher than the market average in the United States, usually indicating a "sell." However, analysts forecast strong future earnings growth of 21% per year, outpacing the market's 12%, which justifies its elevated P/E and suggests that investors are willing to pay a premium for its expected performance.
UPDATE 4-Novo Nordisk sues Hims after short-lived $49 weight-loss pill drama
Novo Nordisk has sued Hims & Hers Health Inc. for patent infringement after Hims launched and then canceled a $49 compounded version of Wegovy. The lawsuit follows FDA backlash against compounded GLP-1 drugs, which has boosted Novo Nordisk's shares and suggests a broader crackdown on such alternative treatments. This development marks a victory for Novo Nordisk in its fight against copycat versions of its GLP-1 drugs, though competitive pressure from Eli Lilly and other compounding pharmacies remains intense.
UPDATE 2-Novo Nordisk surges as Hims pulls $49 weight loss pill under FDA pressure
Novo Nordisk's shares jumped over 8% after telehealth firm Hims & Hers canceled the launch of a $49 compounded weight-loss pill following pressure from the FDA and legal threats. This move is seen by analysts as a broader crackdown by the FDA on unregulated compounded GLP-1 drugs, boosting prospects for branded treatments from Novo Nordisk and Eli Lilly. Despite this victory against copycat drugs, Novo Nordisk faces ongoing pricing pressures and intense competition in the rapidly shifting GLP-1 market.
UPDATE 1-Novo Nordisk shares rise as Hims abandons $49 weight-loss pill
Novo Nordisk's shares jumped after telehealth firm Hims & Hers canceled the launch of a $49 compounded weight-loss pill, following legal threats from Novo and the FDA. This marks a rare victory for Novo in its battle against compounded GLP-1 drugs, though pricing pressures and competition from Eli Lilly and other compounders are expected to intensify. Despite a recent rebound, Novo Nordisk has faced significant market value loss and price pressure.
Regulatory Scrutiny Puts Hims And Hers GLP 1 Growth Story To The Test
Hims & Hers Health (NYSE:HIMS) is facing significant regulatory and legal scrutiny regarding its compounded semaglutide weight-loss pill, which is marketed as a cheaper alternative to Wegovy. The FDA has issued warnings, and the Department of Health and Human Services has referred the company to the Department of Justice for a potential investigation, while Novo Nordisk is also pursuing legal action. This scrutiny has led to a recent decline in HIMS stock price and raises questions about the company's future growth strategy, particularly its reliance on GLP-1 offerings that are now under pressure.
UPDATE 5-US signals crackdown on compounded weight-loss drugs; Hims shares tumble
The U.S. Food and Drug Administration (FDA) announced it would take action against telehealth provider Hims & Hers for its $49 weight-loss pill, citing concerns over quality, safety, and potential violations of federal law. This move, which includes restricting access to drug ingredients and referring Hims to the Department of Justice, caused Hims shares to fall 14.1% in after-hours trade. The FDA's crackdown is a win for companies like Novo Nordisk and Eli Lilly, who have been losing market share to compounded alternatives.
ANALYSIS-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
Hims & Hers' introduction of a $49 compounded version of Novo Nordisk's Wegovy pill has significantly impacted the obesity drug market, raising questions about efficacy, legality, and pricing pressure. This move puts Hims in a regulatory grey zone and threatens the market dominance and investor confidence in major pharmaceutical companies like Novo Nordisk and Eli Lilly. Analysts are divided on the implications for patent value and market access, while the FDA has threatened action against "illegal copycat drugs."
Hims and Novo Nordisk: Compounded Oral Semaglutide Launch Challenges Legal Framework
Hims & Hers has launched an oral semaglutide treatment plan starting at $49 per month, directly competing with Novo Nordisk's recently launched Wegovy pill. This move comes after a contentious prior collaboration between the two companies and could lead to legal action from Novo Nordisk and government agencies, given that oral semaglutide has not been on a shortage list, which generally justifies compounded drugs. Morningstar maintains fair value estimates for both companies, acknowledging the high uncertainty in the oral GLP-1 market and the potential for increased FDA restrictions on compounded drugs.
Hims and Novo Nordisk: Compounded Oral Semaglutide Launch Challenges Legal Framework
Hims & Hers has launched a compounded oral semaglutide treatment plan at a significantly lower price, directly competing with Novo Nordisk’s recently launched Wegovy pill. This move could complicate Novo Nordisk's market trajectory and its efforts to maximize sales before a potential rival drug from Eli Lilly. Analysts expect Hims' launch to trigger legal action from Novo Nordisk and regulatory scrutiny, given that oral semaglutide has not been on a shortage list, raising questions about the legality of the compounded drug.
Hims and Novo Nordisk: Compounded Oral Semaglutide Launch Challenges Legal Framework
Hims & Hers has launched a compounded oral semaglutide directly competing with Novo Nordisk's newly released Wegovy pill. This move raises legal concerns for Hims, as oral semaglutide has not been on a shortage list, operating in a "grey area of legality" that Morningstar judges to be moving closer to a "red line." This launch jeopardizes Novo Nordisk's key focus of maximizing Wegovy's launch ahead of a competing drug from Lilly and is likely to trigger legal action from Novo Nordisk and government agencies.
Hims And Hers Weight Loss Push Faces Novo Nordisk Legal Challenge
Hims & Hers Health has launched a compounded oral semaglutide pill, a low-cost alternative for weight loss, leading to a legal challenge from Novo Nordisk. Novo Nordisk accuses Hims & Hers of illegal mass compounding and threatens legal action, raising questions about patient safety and intellectual property. The dispute is significant for Hims & Hers shareholders due to potential impacts on its market position and pricing power in the competitive GLP-1 weight loss drug market.
(HIMS) Movement Within Algorithmic Entry Frameworks
The article analyzes Hims & Hers Health Inc. Class A (NASDAQ: HIMS) based on algorithmic entry frameworks. It highlights weak sentiment across all time horizons, suggesting a short bias, and details institutional trading strategies including position trading, momentum breakout, and risk hedging strategies. The analysis also covers multi-timeframe signal analysis indicating weak signals across near-term, mid-term, and long-term horizons, along with respective support and resistance levels.
Jack Abraham Board Role Links Hims And Hers To Research Frontline
Jack Abraham, co-founder of Hims & Hers Health (NYSE:HIMS), has been appointed to the governing board of Cold Spring Harbor Laboratory, a prominent biomedical research institution. This appointment connects Hims & Hers to a leading scientific network, potentially influencing its future product development and partnerships in areas like genetics, neuroscience, and cancer research. Investors may view this as a strategic move to align the telehealth company with cutting-edge science in personalized health.
Looking At Hims & Hers Health's Recent Unusual Options Activity
Benzinga's options scanner detected 14 uncommon options trades for Hims & Hers Health (NYSE: HIMS), with a sentiment split between 35% bullish and 50% bearish among large investors. These trades suggest that "whales" are targeting a price range of $30.0 to $100.0 for HIMS over the next three months. The article highlights significant call and put activities and provides an overview of Hims & Hers Health's business model and current market status.
Is It Too Early To Reconsider Hims & Hers Health (HIMS) After Recent Share Price Pullback?
Hims & Hers Health (HIMS) has experienced recent share price declines, prompting a valuation analysis. A Discounted Cash Flow (DCF) model suggests the stock is undervalued by 53.3%, with an intrinsic value of $63.39 compared to its current price of $29.62. However, its Price-to-Earnings (P/E) ratio of 50.40x appears overvalued when compared to the Healthcare industry average and Simply Wall St's Fair Ratio of 27.16x.
End Of Novo Nordisk GLP-1 Deal Could Be A Game Changer For Hims & Hers Health (HIMS)
Hims & Hers Health recently ended its partnership with Novo Nordisk, impacting its access to branded GLP-1 weight-loss drugs and shifting its focus to compounded alternatives amidst regulatory and margin challenges. This move, coupled with slowing growth predictions and increased telehealth competition, has prompted analysts and investors to re-evaluate the company's future growth drivers and investment narrative. The article suggests this makes Hims & Hers Health's stock more of a "show-me" situation as the company navigates these changes and relies on other initiatives for growth.
Peering Into Hims & Hers Health Inc's Recent Short Interest
Hims & Hers Health Inc (NYSE: HIMS) has seen a 3.52% increase in its short interest, with 67.10 million shares now sold short, representing 36.46% of its float. This rise indicates a more bearish sentiment among investors, and the company's short interest is significantly higher than its peer group average of 8.15%. It would take traders an average of 6.19 days to cover their short positions.
How (HIMS) Movements Inform Risk Allocation Models
This article analyzes Hims & Hers Health Inc. (NASDAQ: HIMS) using AI models to inform risk allocation. It highlights a weak near and mid-term sentiment with a neutral long-term outlook, indicating elevated downside risk. The analysis provides specific institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis to guide risk management and trading decisions.
Here's How Much $100 Invested In Hims & Hers Health 5 Years Ago Would Be Worth Today
This article analyzes the hypothetical return of a $100 investment in Hims & Hers Health (NYSE: HIMS) made five years ago. It reveals that the investment would now be worth $223.12, demonstrating an annualized return of 15.61%, which outperformed the market by 3.23%. The piece emphasizes the significant impact of compounded returns over time.
Okupe, CFO of Hims & Hers, sells $275k in HIMS stock
Oluyemi Okupe, CFO of Hims & Hers Health, Inc., sold 9,067 shares of Class A Common Stock for approximately $275,113 on January 20, 2026, after exercising options for the same number of shares. Following these transactions, Okupe directly owns 91,617 shares of HIMS, with an additional 7,853 shares held indirectly. This sale was conducted under a Rule 10b5-1 trading plan, and the company has recently been subject to various analyst ratings and increased competition in the weight management market.
Okupe, CFO of Hims & Hers, sells $275k in HIMS stock
Oluyemi Okupe, CFO of Hims & Hers Health, Inc., sold 9,067 shares of Class A Common Stock for approximately $275,113 on January 20, 2026, as part of a Rule 10b5-1 trading plan. On the same day, Okupe exercised options to acquire 9,067 shares, and now directly owns 91,617 HIMS shares, with an additional 7,853 shares held indirectly. This transaction comes amidst various analyst reports on Hims & Hers Health, with concerns raised about revenue growth and increased competition, particularly from Amazon Pharmacy.
Okupe, CFO of Hims & Hers, sells $275k in HIMS stock By Investing.com
Oluyemi Okupe, CFO of Hims & Hers Health, Inc. (NASDAQ: HIMS), sold 9,067 shares of Class A Common Stock for approximately $275,113 on January 20, 2026, after exercising options to acquire the same number of shares. These transactions were carried out under a Rule 10b5-1 trading plan. The article also mentions recent analyst reports from Morgan Stanley, Evercore ISI, and BofA Securities concerning Hims & Hers' revenue growth, valuation, and market challenges, including increased competition from Amazon Pharmacy.
Okupe, CFO of Hims & Hers, sells $275k in HIMS stock By Investing.com
Oluyemi Okupe, CFO of Hims & Hers Health, Inc. (NASDAQ: HIMS), sold 9,067 shares of Class A Common Stock for approximately $275,113 on January 20, 2026, after exercising options for an equivalent number of shares. Following these transactions, Okupe directly owns 91,617 shares, with an additional 7,853 held indirectly. This move comes amidst various analyst reports and increased competition for Hims & Hers Health, particularly with Amazon Pharmacy now offering Novo Nordisk's Wegovy.
Is Hims & Hers (HIMS) Using Zava to Balance GLP-1 Uncertainty with Broader Platform Ambitions?
Hims & Hers Health has expanded its telehealth platform beyond its original focus, entering diagnostics, hormone health, and weight-loss support, and extending its reach into Europe through the Zava acquisition. This expansion aims to diversify its offerings and international growth, potentially offsetting risks associated with regulatory scrutiny and competition in its GLP-1 weight-loss sector. The company projects significant revenue and earnings growth by 2028, with its fair value estimated at $44.36, presenting a 42% upside from its current price.
A Look At Hims & Hers Health (HIMS) Valuation As Amazon Targets The Weight Loss Segment
Hims & Hers Health (HIMS) faces increased competition in the weight loss segment as Amazon Pharmacy enters the market with Novo Nordisk's Wegovy. Despite a recent share price decline, longer-term shareholders have seen substantial gains. The article explores HIMS' valuation, noting narratives that suggest it is undervalued based on future growth in diversified health categories, while also highlighting valuation risks due to its high P/E ratio compared to industry averages.
Is It Too Late To Consider Hims & Hers Health (HIMS) After Its 4x Three-Year Surge?
This article analyzes Hims & Hers Health (HIMS) stock after its significant three-year surge. Using valuation tools like Discounted Cash Flow (DCF) and Price/Earnings (P/E) ratios, it suggests the stock might be undervalued by DCF analysis but overvalued based on its P/E ratio compared to industry averages and Simply Wall St's Fair Ratio. The article encourages investors to consider different valuation narratives and their own financial situations before making investment decisions.
Trading Systems Reacting to (HIMS) Volatility
Hims & Hers Health Inc. Class A (NASDAQ: HIMS) is experiencing weak near- and mid-term sentiment, despite a previously positive long-term outlook. The stock is currently undergoing a breakdown, with elevated downside risk as long-term support signals are no longer present. Stock Traders Daily's AI models have generated three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to manage the volatility.
How Hims & Hers Health Inc. Class A (HIMS) Affects Rotational Strategy Timing
This article analyzes Hims & Hers Health Inc. (HIMS) through a rotational strategy timing lens, highlighting weak near and mid-term sentiment that could challenge a positive long-term outlook. Predictive AI models have generated distinct trading strategies, including long, breakout, and short positions, adapted for different risk profiles. The analysis further provides multi-timeframe signal analysis, showing current support and resistance levels.
Unpacking the Latest Options Trading Trends in Hims & Hers Health
Investors have shown a bearish sentiment towards Hims & Hers Health (NYSE: HIMS), with notable options trading activity detected by Benzinga's scanner. A significant number of uncommon options trades, including both puts and calls, indicate that major market movers are focusing on a price band between $3.0 and $105.0. This suggests that some market participants may have insights into upcoming price movements for HIMS.
How Do Investors Really Feel About Hims & Hers Health Inc?
Hims & Hers Health Inc's short interest has declined by 3.72% since its last report, with 64.82 million shares sold short, representing 35.22% of its float. While this suggests a potentially more bullish sentiment compared to past reports, the short interest is still higher than the peer group average of 7.95%. Investors should be aware that less shares are being shorted, though this doesn't guarantee a near-term stock rise.
(HIMS) Risk Channels and Responsive Allocation
This article provides a stock analysis for Hims & Hers Health Inc. Class A (NASDAQ: HIMS), highlighting weak near and mid-term sentiment despite a long-term positive outlook. It details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for support and resistance levels. The analysis reports elevated downside risk due to a lack of additional long-term support signals.
Hims & Hers Health (HIMS) Valuation Check After $200M Ohio Expansion and Ongoing International Growth
Hims & Hers Health (HIMS) is expanding significantly with a new $200 million Ohio facility and international growth in the U.K. and Canada, fueling strong year-to-date share price performance. While a narrative valuation suggests the stock is 59.6% undervalued with a fair value of $86.09, market ratios indicate it's richly priced at 59.2 times earnings, reflecting high expectations. Investors should consider both the growth potential and potential risks like regulatory scrutiny and increased competition.
(HIMS) Movement as an Input in Quant Signal Sets
This article from Stock Traders Daily discusses Hims & Hers Health Inc. (NASDAQ: HIMS), highlighting strong sentiment across all time horizons supporting an overweight bias. It presents specific AI-generated trading strategies for HIMS, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The analysis also points to an exceptional 112.6:1 risk-reward setup.
HIMS CLASS ACTION FILED: Kessler Topaz Meltzer & Check, LLP Reminds Investors - a Securities Fraud Class Action Lawsuit Has Been Filed Against Hims & Hers Health, Inc. (HIMS)
Kessler Topaz Meltzer & Check, LLP announced that a securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS). The lawsuit alleges that Hims & Hers made materially false or misleading statements and failed to disclose that it was deceptively promoting illegitimate versions of Wegovy, which put patient safety at risk and jeopardized its collaboration with Novo Nordisk. Investors who purchased Hims & Hers securities between April 29, 2025, and June 23, 2025, are encouraged to contact the firm by August 25, 2025, to discuss potentially being appointed as a lead plaintiff.
Boughton, Hims & Hers health CLO, sells $112k in shares
Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (NASDAQ:HIMS), sold 2,637 shares valued at $112,151 on November 10, 2025. This transaction was executed under a Rule 10b5-1 trading plan. The sale followed a quarter where Hims & Hers exceeded analyst expectations in revenue, EBITDA, and EPS, despite narrowing its 2025 revenue guidance.
Hims & Hers Health effects new up to $250M stock buyback program, shares up ~2% (HIMS:NYSE)
Hims & Hers Health (HIMS) has announced a new share repurchase program of up to $250 million for its outstanding Class A common stock, to be executed over the next three years. This news follows the completion of its previous $100 million buyback program and led to a pre-market stock increase of 2.76% to $38.00.
Hims & Hers Health board approves $250 million share repurchase program
Hims & Hers Health (NYSE:HIMS) announced its board has approved a new $250 million share repurchase program for its Class A common stock, set to expire in November 2028. This follows the complete utilization of a previous $100 million repurchase program. The company will repurchase shares through various methods, and the program can be suspended or discontinued at any time.
Hims & Hers Health stock rises after announcing $250 million buyback program
Hims & Hers Health (HIMS) stock rose in premarket trading after the company announced a $250 million share repurchase program. The buyback program is authorized for two years and will commence immediately. The company expects the program to be immediately accretive to shareholder value.
Hims & Hers health authorizes $250 million share repurchase program
Hims & Hers Health, Inc. has announced that its Board of Directors authorized a $250 million share repurchase program. This program is in effect for one year, allowing the company to repurchase shares of its common stock through various methods.
Hims & Hers Health, Inc. Announces $250 Million Share Repurchase Program Authorization
Hims & Hers Health, Inc. has announced a new share repurchase program, authorizing up to $250 million of its Class A common stock over the next three years. This program follows the successful completion of a previous $100 million repurchase initiative. The company aims to capitalize on perceived valuation disconnects and deliver value to shareholders, leveraging its strong balance sheet and projected cash flows.
Hims & Hers Health Announces New Share Repurchase Program
Hims & Hers Health, Inc. has announced a new share repurchase program authorizing the company to buy back up to $250 million in Class A stock. This program will expire on November 11, 2028, and repurchases will be discretionary based on market conditions. This follows the full utilization of a previous $100 million repurchase program by November 2025.
Why Are Hims & Hers Health (HIMS) Shares Soaring Today
Shares of telehealth company Hims & Hers Health (HIMS) jumped 6.9% after reporting strong third-quarter 2025 revenue growth, which beat analysts' forecasts. Despite lower-than-expected profit and future guidance, investors focused on the company's robust sales performance and its recent expansion into GLP-1 weight-loss treatments. The stock also saw a boost from JPMorgan Chase & Co. disclosing a significant passive stake in the company.
Hims & Hers Health (HIMS) Revenue Growth Forecast Tops Market, Elevating Debate on Valuation Premium
Hims & Hers Health (HIMS) is projected to see strong revenue growth despite a decline in net profit margins, leading to a debate about its high price-to-earnings ratio compared to the broader market and peers. Analysts forecast continued growth fueled by international expansion and AI integration, yet the stock trades at a significant premium, raising questions about whether its future potential justifies its current valuation. The company's current share price is below its DCF fair value, but analyst price targets hover close to the current price, indicating ongoing disagreement on its long-term outlook.
Rosen Law Firm Encourages Hims & Hers Health, Inc. Investors to Inquire About Securities Class Action Investigation – HIMS
The Rosen Law Firm has launched an investigation into potential securities claims against Hims & Hers Health, Inc. following allegations of misleading business information. This probe comes after Novo Nordisk terminated its collaboration with Hims & Hers, citing concerns about illegal mass compounding and deceptive marketing, which led to an over 28% drop in Hims & Hers' stock. Investors are encouraged to contact the firm to join a prospective class action seeking compensation for their losses.
LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc.
Levi & Korsinsky LLP has issued a correction regarding a securities fraud class action lawsuit against Hims & Hers Health, Inc. The firm clarified that Glancy Prongay & Murray LLP, not Levi & Korsinsky, filed the lawsuit. The class action alleges that Hims & Hers Health, Inc. made false statements regarding "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy®" which put patient safety at risk and could lead to termination of their collaboration with Novo Nordisk.
